Rapid remineralization of multiple disseminated bone lesions after high-dose cytarabine in a patient with isolated myeloid sarcoma

European Journal of Haematology
Sebastian BrählerSascha Ansén

Abstract

Isolated myeloid sarcoma is a rare presentation of acute myeloid leukemia. There are limited data available concerning the prognostic relevance and the right treatment strategy for this clinical scenario. Here, we report a case of acute myeloid leukemia with extensive lesions and fractures in multiple bones in a 64-yr-old male patient. Remarkably, treatment with a high-dose cytarabine regimen led to rapid remineralization of all bone lesions and recovery of the patient's mobility within a few weeks. Thereby, surgical treatment and radiotherapy could be avoided, supporting the role of intensive induction and standard consolidation chemotherapy as first-line treatment for myeloid sarcoma.

References

Jun 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M EshghabadiI Carr
Jul 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J C ByrdN A Dawson
Apr 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M S TallmanD Variakojis
Feb 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J C ByrdC D Bloomfield
Jul 29, 2011·Blood·Richard L BakstJoachim Yahalom
Oct 4, 2011·International Journal of Radiation Oncology, Biology, Physics·Richard BakstJoachim Yahalom

❮ Previous
Next ❯

Citations

Apr 29, 2016·Oncology Letters·Xin WangSheng-Xiang Xiao

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.